Skip to main content

Breadcrumb

  1. Home

Spring 2021

30-day Risk Standardized Morbidity and Mortality Composite following Transcatheter Aortic Valve Replacement (TAVR)

  • The TAVR 30-day morbidity/mortality composite is a hierarchical, multiple outcome risk model that estimates risk standardized results (reported as a “site difference”) for the purpose of benchmarking site performance. This measure estimates hospital risk standardized site difference for 5 endpoints (death from all causes, stroke, major or life-threatening bleeding, acute kidney injury, moderate or severe paravalvular aortic regurgitation) within 30 days following transcatheter aortic valve replacement.

    CBE ID
    3610

Adult Immunization Status

  • The percentage of adults 19 years of age and older who are up-to-date on Advisory Committee on Immunization Practice (ACIP) recommended routine vaccines for influenza, tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap), zoster and pneumococcal.

    CBE ID
    3620

Chlamydia Screening in Women (CHL)

  • The percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.

    CBE ID
    0033

Composite weighted average for 3 CT Exam Types: Overall Percent of CT exams for which Dose Length Product is at or below the size-specific diagnostic reference level (for CT Abdomen-pelvis with contrast/single phase scan, CT Chest without contrast/single

  • Measure title continued: Composite weighted average for 3 CT Exam Types: Overall Percent of CT exams for which Dose Length Product is at or below the size-specific diagnostic reference level (for CT Abdomen-pelvis with contrast/single phase scan, CT Chest without contrast/single phase scan and CT Head/Brain without contrast/single phase scan)

    CBE ID
    3621

Concurrent Use of Opioids and Benzodiazepines (COB)

  • The percentage of individuals >=18 years of age with concurrent use of prescription opioids and benzodiazepines during the measurement year.

    A lower rate indicates better performance.

    CBE ID
    3389

Contraceptive Care - Access to LARC

  • Percentage of women aged 15-44 years at risk of unintended pregnancy that is provided a long-acting reversible method of contraception (i.e., implants, intrauterine devices or systems (IUD/IUS)).

    It is an access measure because it is intended to identify very low rates (less than 1-2%) of long-acting reversible methods of contraception (LARC), which may signal barriers to LARC provision.

    CBE ID
    2904

Contraceptive Care - Postpartum

  • Among women ages 15 through 44 who had a live birth, the percentage that is provided:
    1) A most effective (i.e., sterilization, implants, intrauterine devices or systems (IUD/IUS)) or moderately (i.e., injectables, oral pills, patch, or ring) effective method of contraception within 3 and 60 days of delivery.

    2) A long-acting reversible method of contraception (LARC) within 3 and 60 days of delivery.

    CBE ID
    2902

Contraceptive Care – Most & Moderately Effective Methods

  • The percentage of women aged 15-44 years at risk of unintended pregnancy that is provided a most effective (i.e., sterilization, implants, intrauterine devices or systems (IUD/IUS)) or moderately effective (i.e., injectables, oral pills, patch, or ring) method of contraception.

    The measure is an intermediate outcome measure because it represents a decision that is made at the end of a clinical encounter about the type of contraceptive method a woman will use, and because of the strong association between type of contraceptive method used and risk of unintended pregnancy.

    CBE ID
    2903